We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · April 06, 2021

Clopidogrel vs Ticagrelor or Prasugrel After Primary PCI According to CYP2C19 Genotype

Circulation: Cardiovascular Interventions


Additional Info

Disclosure statements are available on the authors' profiles:

Circulation: Cardiovascular Interventions
Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype: A POPular Genetics Subanalysis
Circ Cardiovasc Interv 2021 Mar 16;[EPub Ahead of Print], DMF Claassens, TO Bergmeijer, GJA Vos, RS Hermanides, AWJ van 't Hof, P van der Harst, E Barbato, C Morisco, RM Tjon Joe Gin, FW Asselbergs, A Mosterd, JR Herrman, WJM Dewilde, PWA Janssen, JC Kelder, BK Mahmoodi, VHM Deneer, JM Ten Berg

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading